Add BrightSurf on Google Email

Can targeted therapies be applied to patients with Alzheimer's?

University of Utah researchers have developed a targeted therapy approach using alpha particles to break down harmful amyloid beta plaques, potentially slowing the devastating neurodegenerative disease. The treatment, called Targeted Alpha Therapy, delivers particles directly to the plaques while minimizing damage to healthy tissues.

SourceUniversity of Utah·JournalJournal of Nuclear Medicine·TypeObservational study·DateAug 1, 2024

Aging-related genomic culprit found in Alzheimer’s disease

Researchers developed a method to study aged neurons in the lab without a brain biopsy, revealing aspects of cells' genomes linked to late-onset Alzheimer's development. The technique suggests new treatment strategies targeting retrotransposable elements and early intervention to slow disease progression.

SourceWashU Medicine·JournalScience·TypeExperimental study·DateAug 1, 2024

Public health measures that reduce dementia risk could save up to £4bn

A new study suggests that public health interventions, such as reformulating food products and introducing low emission zones, could yield significant cost savings and QALY gains in England. The interventions studied could save up to £4bn by reducing dementia rates and helping people live longer and healthier.

SourceUniversity College London·JournalThe Lancet Healthy Longevity·TypeComputational simulation/modeling·DateJul 31, 2024

Published research from the Parkinson’s Foundation shows genetic variants are more common in people with Parkinson’s disease than originally thought

The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.

SourceParkinson's Foundation·JournalBrain·TypeObservational study·DateJul 29, 2024

“Prelude” to neuromuscular disease SMA may offer chances for better treatment

Researchers found anomalies in embryonic development of individuals with spinal muscular atrophy (SMA), which could lead to new treatment options. These abnormalities were recreated in laboratory-grown tissue cultures called organoids, revealing key insights into the disease's progression.

SourceDZNE - German Center for Neurodegenerative Diseases·JournalCell Reports Medicine·TypeExperimental study·DateJul 26, 2024

Antisense oligonucleotide treatment shows promise in treating Parkinson's disease progression

Researchers from Tokyo Medical and Dental University demonstrate a proof of concept for antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. The treatment, involving antisense oligonucleotides, effectively reduces Lewy pathology-like neuronal inclusion by over 90%.

SourceTokyo Medical and Dental University·JournalActa Neuropathologica Communications·DateJul 25, 2024

Multiple concussions in rugby players change proteins linked to neurodegenerative diseases

A study by Durham University found that retired rugby players with multiple concussions have higher levels of proteins linked to neurodegenerative diseases, such as Alzheimer's and motor neurone disease. The research suggests monitoring athletes' blood for these biomarkers may help diagnose early disease and prevent future development.

SourceDurham University·JournalInternational Journal of Molecular Sciences·TypeObservational study·DateJul 16, 2024

Protein droplets likely don’t cause Parkinson’s

Researchers investigated the relationship between protein aggregation and liquid-liquid phase separation, finding that droplet formation may actually protect against aggregation. The study, led by Paul Scherrer Institute, used over 500 conditions to test the behavior of alpha-synuclein proteins.

SourcePaul Scherrer Institute·JournalAdvanced Science·TypeExperimental study·DateJul 15, 2024

Sant Pau researchers discover a new gene that causes ALS

A study by Sant Pau Research Institute identified a new mutation in the ARPP21 gene linked to amyotrophic lateral sclerosis (ALS) in 10 patients from 7 unrelated families. The finding suggests that ARPP21 is a novel ALS-causing gene with potential for personalized therapies and diagnosis.

SourceInstitut de Recerca Sant Pau (Sant Pau Research Institute)·JournalJournal of Neurology Neurosurgery & Psychiatry·TypeExperimental study·DateJul 12, 2024

Potential new target for early treatment of Alzheimer's disease

A study found that targeting heparan sulfate-modified proteins improves cell repair, rescues neuron loss and reverses cellular changes associated with neurodegenerative diseases. Disrupting these proteins promotes autophagy-dependent cell repair and reverses early cellular problems in models of Alzheimer's.

SourcePenn State·JournaliScience·TypeExperimental study·DateJul 2, 2024

Neuroscience research leverages stem cells to understand how neurons connect and communicate in the brain

Researchers at Colorado State University used human stem cells to study synaptic connections in the brain, focusing on GABAergic synapses. They found that Gephyrin promotes autonomous assembly of these synapses, which can develop independently of neuronal communication. This understanding could lead to new treatments for neurological d...

SourceColorado State University·JournalProceedings of the National Academy of Sciences·DateJun 26, 2024

Slipping a note to a neighbor: The cellular way

Researchers from PSI and ETH Zurich studied connexin-36 gap junction channels and found that antimalarial drug mefloquine binds to the channels, potentially explaining its severe side effects. The study provides new insights into how drugs interact with connexins and may lead to the development of therapies for neurological diseases.

SourcePaul Scherrer Institute·JournalCell Discovery·TypeExperimental study·DateJun 26, 2024

Landmark Nature Medicine study reports promising new treatment reduces suffering in Sanfilippo syndrome

A landmark clinical trial collaboration has reported significant improvements in neurobehavioral and functional outcomes for children with moderate to advanced stages of Sanfilippo syndrome. The study found anakinra, a recombinant interleukin-1 receptor antagonist, to be safe and effective in reducing disease symptoms.

SourceThe Lundquist Institute·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJun 21, 2024

AI-driven tool for distinguishing Lewy body dementia via changes in vocal emotional expression

A new AI-driven tool can accurately diagnose Lewy body dementia by analyzing changes in vocal emotional expressions. The study found that individuals with Lewy body dementia exhibited more negative and calmer emotional expressions compared to those with Alzheimer's disease and healthy controls.

SourceUniversity of Tsukuba·JournalAlzheimer s & Dementia Diagnosis Assessment & Disease Monitoring·DateJun 4, 2024

Magnetic microcoils unlock targeted single-neuron therapies for neurodegenerative disorders

Researchers have developed a magnetic coil array called MagPatch that can stimulate individual neurons with precision. The device uses soft magnetic materials to boost the magnetic field, reducing the need for high current levels.

SourceAmerican Institute of Physics·JournalJournal of Vacuum Science & Technology B Microelectronics and Nanometer Structures Processing Measurement and Phenomena·DateApr 23, 2024

Cleveland clinic researchers use AI to improve Alzheimer’s treatment through the ‘gut-brain axis’

Researchers used machine learning to analyze over 1.09 million potential metabolite-receptor pairs and predict the likelihood that each interaction contributed to Alzheimer's disease. The study found a protective metabolite called agmatine interacting with a receptor called CA3R in brain cells, reducing CA3R levels and lowering phospho...

SourceCleveland Clinic·JournalCell Reports·DateApr 22, 2024

A new therapeutic target for traumatic brain injury

Researchers at Gladstone Institutes have identified a blood coagulation protein, fibrin, as the culprit behind toxic inflammation and neuron loss after a major head injury. This finding can inform new treatment strategies for traumatic brain injuries, which often lead to dementia, depression, and difficulty concentrating.

SourceGladstone Institutes·JournalJournal of Neuroinflammation·TypeExperimental study·DateApr 19, 2024

Older brain cells linger unexpectedly before their death

Researchers discovered that mature oligodendrocytes, critical for brain function, can survive for up to 45 days after a fatal trauma, defying the classical programmed cell-death pathway. This finding opens new avenues for understanding and potentially preventing damage caused by aging and neurodegenerative diseases.

SourceDartmouth College·JournalJNeurosci·TypeExperimental study·DateMar 28, 2024

New treatment target identified for Alzheimer's disease

Researchers have identified PDE4B as a potential target for treating Alzheimer's disease, where reducing its activity shows promise in improving memory and glucose metabolism. The study suggests that this approach may also protect against other forms of dementia, such as Huntington's disease.

SourceLancaster University·JournalNeuropsychopharmacology·TypeExperimental study·DateMar 26, 2024

Study links long-term consumption of reused deep-fried oil with increased neurodegeneration

Rats consuming reheated sesame or sunflower oil showed increased oxidative stress and inflammation in the liver, leading to significant damage in the colon and changes in endotoxins. The study suggests that long-term deep-fried oil consumption may contribute to neurodegeneration and highlight the need for further research on this topic.

Movement disorder ALS and cognitive disorder FTLD show strong molecular overlaps, new study shows

A recent study published in Cell reveals significant similarities between amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), two distinct neurological disorders. The research found shared gene expression patterns across various brain regions, suggesting potential therapeutic targets for both conditions.

SourcePicower Institute at MIT·JournalCell·TypeExperimental study·DateMar 22, 2024

Can modified RNA heal neurodegeneration?

Researchers at University of Pittsburgh are developing a platform to genetically modify glia cells using bioengineering modified RNAs. The goal is to increase or decrease disease-relevant genes in astrocytes or microglia to potentially treat Alzheimer's disease and other neurodegenerative disorders.

Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial

A clinical trial at NIH demonstrated that experimental gene therapy slowed loss of motor function in patients with giant axonal neuropathy, a fatal childhood disease. The treatment also showed signs of regeneration in sensory nerves, offering new hope for those affected.

SourceNIH/National Institute of Neurological Disorders and Stroke·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateMar 20, 2024

Shedding new light on brain calcification

Researchers at the University of Bergen have identified a new gene linked to primary familial brain calcification (PFBC), a rare neurodegenerative condition. The discovery provides new insight into how brain calcifications occur and may help explain the development of dementia.

SourceThe University of Bergen·JournalNature Communications·DateMar 14, 2024

‘Curved’ walking and a depth camera: new tool detects early cognitive decline

A first-of-its-kind study uses gait analysis to detect subtle impairments in older adults with mild cognitive impairment, suggesting curved path walking as a more sensitive detection method. The novel system employs a non-invasive depth camera to record gait and provides detailed information on functional performance.

SourceFlorida Atlantic University·JournalJournal of Alzheimer s Disease Reports·TypeImaging analysis·DateMar 12, 2024

Why some RNA drugs work better than others

Researchers have discovered why some RNA-splicing drugs work better than others, revealing a key factor that impacts treatment efficacy. By analyzing the interactions between drugs and RNA, they found that combining splice-modifying drugs targeting the same gene segment can lead to greater therapeutic effects.

SourceCold Spring Harbor Laboratory·JournalNature Communications·DateMar 6, 2024

Researchers uncover a potential genetic marker associated with better survival outcomes in patients with head and neck cancer

A study published in Cancer Research Communications reveals a potential genetic marker associated with better survival outcomes in patients with head and neck cancer. The researchers found that the presence of a specific genetic variant and higher expression of the GAN gene product gigaxonin may contribute to improved survival rates.

SourceUniversity of California - Los Angeles Health Sciences·JournalCancer Research Communications·DateFeb 29, 2024

Neurons help flush waste out of brain during sleep

Scientists at Washington University School of Medicine discovered that neurons coordinate to produce rhythmic waves that propel fluid through dense brain tissue, washing the tissue in the process. This finding has implications for delaying or preventing neurodegenerative diseases by enhancing the brain's cleaning abilities.

SourceWashU Medicine·JournalNature·TypeExperimental study·DateFeb 28, 2024